Study to investigate safety and tolerability of a single dose of AZD6482

Study identifier:D1700C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomised, double-blind, placebo-controlled Phase I study to assess the tolerability, safety, pharmacokinetic, and pharmacodynamic properties of AZD6482, alone and co-administered with ASA, after single ascending intravenous doses to healthy male subjects

Medical condition

Antiplatelet effect

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD6482, Placebo

Sex

Male

Actual Enrollment

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Jan 2008

Primary Completion Date: 01 May 2008

Study Completion Date: 01 May 2008

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: 1	Drug: AZD6482 0,9-364,5 mg administrated through intravenous infusion over 3 hours
Placebo Comparator: 2	-

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1201&filename=CSR-D1700C00001.pdf
Download
CSR-D1700C00001.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Marianne Hartford

AstraZeneca R&D, Clinical Pharmacology Unit, Sahlgrenska University Hospital, Göteborg, Sweden